Histamine receptors and cancer pharmacology : an update

• Autores: Massari, Noelia A.; Nicoud, Melisa Beatriz; Medina, Vanina Araceli
• Año de publicación: 2018
• Idioma: inglés
• Tipo de recurso: artículo
• Fuente: British Journal of Pharmacology. December 2018
• Materia: HISTAMINA; CANCER; TUMORES; MARCADORES BIOLOGICOS
• Institución: Pontificia Universidad Católica Argentina

Fil: Massari, Noelia A. Universidad Nacional de la Patagonia San Juan Bosco. Facultad de Ciencias Naturales y Médicas. Departamento de Inmunología; Argentina
Fil: Nicoud, Melisa Beatriz. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas. Laboratorio de Biología Tumoral e Inflamación; Argentina
Fil: Nicoud, Melisa Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Medina, Vanina Araceli. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas. Laboratorio de Biología Tumoral e Inflamación; Argentina
Fil: Medina, Vanina Araceli. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Medina, Vanina Araceli. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Laboratorio de Radioisótopos; Argentina
Abstract: In the present review, we will discuss the recent advances in the understanding of the role of histamine and histamine receptors in cancer biology. The controversial role of the histaminergic system in different neoplasias including gastric, colorectal, oesophageal, oral, pancreatic, liver, lung, skin, blood and breast cancers will be reviewed. The expression of histamine receptor subtypes, with special emphasis on the histamine H4 receptor, in different cell lines and human tumours, the signal transduction pathways and the associated biological responses as well as the in vivo treatment of experimental tumours with pharmacological ligands will be described. The presented evidence demonstrates that histamine regulates cancer-associated biological processes during cancer development in multiple cell types, including neoplastic cells and cells in the tumour micro-environment. The outcome will depend on tumour cell type, the level of expression of histamine receptors, signal transduction associated with these receptors, tumour micro-environment and histamine metabolism, reinforcing the complexity of cancer disease. Findings show the pivotal role of H4 receptors in the development and progression of many types of cancers, and considering its immunomodulatory properties, the H4 receptor appears to be the most promising molecular therapeutic target for cancer treatment within the histamine receptor family. Furthermore, the H4 receptor is differentially expressed in tumours compared with normal tissues, and in most cancer types in which data are available, H4 receptor expression is associated with clinicopathological characteristics, suggesting that H4 receptors might represent a novel cancer biomarker.